Clinical Trial Update: Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing myocet (liposomal doxorubicin) plus cyclophosphamide with versus without metformin as first-line treatment for HER2-negative me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Myocet (liposomal doxorubicin)
• metformin (metformin)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Status: COMPLETED